Table 5.
ARRIVE checklist for results (item number 15, 16, 17), discussion (item number 18, 19 and 20)
| Item | Number | Recommendation | Yes (%) | No (%) | 95% CI |
|---|---|---|---|---|---|
| Results | |||||
| Numbers analyzed | 15 | (a) Report the number of animals in each group included in each analysis. Report absolute numbers (e.g., 10/20, not 50%) | 161 (100) | 0 | 1 (0.97-1) |
| (b) If any animals or data were not included in the analysis, explain why | 0 | 161 | - | ||
| Outcomes and estimation | 16 | Report the results for each analysis carried out, with a measure of precision (e.g., SE or CI) | 161 (100) | 0 | 1 (0.97-1) |
| Adverse events | 17 | (a) Give details of all important adverse events in each experimental group | 0 | 161 (100) | - |
| (b) Describe any modifications to the experimental protocols made to reduce adverse events | 0 | 161 (100) | - | ||
| Discussion | |||||
| Interpretation/scientific implications | 18 | (a) Interpret the results, taking into account the study objectives and hypotheses, current theory, and other relevant studies in the literature | 161 (100) | 0 | 1 (0.97-1) |
| (b) Comment on the study limitations including any potential sources of bias, any limitations of the animal model, and the imprecision associated with the results | 8 (4.97) | 153 (95.03) | 0.04 (0.02-0.09) | ||
| (c) Describe any implications of your experimental methods or findings for the replacement, refinement, or reduction (the 3 Rs.) of the use of animals in research | 0 | 161 (100) | - | ||
| Generalisability/translation | 19 | Comment on whether, and how, the findings of this study are likely to translate to other species or systems, including any relevance to human biology | 0 | 161 (100) | - |
| Funding | 20 | List all funding sources and the role of the funder (s) in the study | 55 (34.16) | 106 (65.84) | 0.34 (0.27-0.41) |
SE=Standard error, CI=Confidence interval